Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPN-101 in Adult Healthy Volunteers
NCT03748836Phase 1Completed
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acazicolcept in systemic lupus erythematosus (SLE), graft-versus-host disease (GVHD) and psoriatic arthritis (PsA) (4 arms), sponsored by Alpine Immune Sciences, Inc. Primary endpoint: Safety, as assessed by adverse events according to CTCAE v5.0. Started Jan 2019; status: completed.
02
Drugs
acazicolcept
03
Conditions
systemic lupus erythematosus (SLE)graft-versus-host disease (GVHD)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03748836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748836.